BioSight
Companies
Verastem, Inc. logo

VSTM

NASDAQNEEDHAM, MA
Verastem, Inc.

Verastem develops small-molecule cancer drugs targeting protein pathways involved in tumor growth and survival, with marketed product AVMAPKI FAKZYNJA CO-PACK (a combination of avutometinib and defactinib) and pipeline candidates including avutometinib as a RAF/MEK inhibitor, defactinib as a FAK inhibitor, and VS-7375 as a KRAS G12D inhibitor. Verastem is conducting multiple clinical trials (RAMP 201, RAMP 201J, RAMP 205, RAMP 301, and VS-7375 trials) to evaluate these programs across different indications and has a collaboration with GenFleet Therapeutics.

Price history not yet available for VSTM.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar